What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Deucrictibant demonstrated a highly significant reduction in HAE attack frequency compared to placebo in the Phase 2 trial, achieving an 84.5% reduction in attacks. While direct comparisons to standard of care (lanadelumab) are lacking, the efficacy shown is comparable to existing therapies, indicating a clear clinical advantage.
Does the economic case hold at the expected price? — Cost effectiveness
While the exact pricing of deucrictibant is not yet available, it is expected to be high. The cost-effectiveness will depend on the pricing strategy and the potential savings from reduced acute treatment costs. Current evidence suggests it may not be cost-saving overall, but could be cost-effective if priced appropriately.
Is there quality-of-life evidence payers weigh? — Quality of life
The trial utilized validated instruments like the AE-QoL and TSQM, showing significant improvements in quality of life and treatment satisfaction. However, the absence of generic utility data (e.g., EQ-5D) limits the ability to quantify QALY gains directly.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Deucrictibant has shown an excellent safety profile with no serious adverse events reported in the Phase 2 trial. The absence of significant adverse effects compared to existing therapies supports its favorable safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The trial used placebo as a comparator, which is ethically acceptable but does not provide direct evidence against current standards of care like lanadelumab. This introduces some uncertainty regarding its relative efficacy.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population included adults with HAE Type I or II, reflecting the intended patient population for prophylaxis. However, pediatric data is lacking, which is a gap in representativeness.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Deucrictibant can be easily integrated into existing care pathways as it does not require new diagnostic tests or significant changes in treatment protocols. Its oral administration simplifies the treatment process.
Are the wider system costs understood? — Resource Use and Cost Implications
The introduction of deucrictibant is expected to incur high drug costs, but it may reduce costs associated with acute treatments. However, the overall budget impact remains uncertain until pricing is established.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a well-designed Phase 2 RCT with significant results. However, the small sample size and lack of peer-reviewed publication at this stage introduce some limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are uncertainties regarding long-term safety and efficacy, adherence in real-world settings, and economic modeling assumptions. While the evidence is strong, these factors could influence the overall assessment.
